Terran Biosciences ("Terran"), a biotech platform company dedicated to the 
development of transformational therapeutics for neurological and psychiatric 
diseases, has entered into an agreement with Concert Pharmaceuticals 
("Concert") to acquire a portfolio of Concert's CNS therapeutics and 
accompanying intellectual property.

Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg
 
These deuterated compounds represent next-generation therapeutics with 
applications across several different psychiatric and neurological conditions. 
Terran plans to quickly accelerate the development of these compounds as 
important complements to a growing pipeline of both early-stage and late-stage 
therapeutics and technologies in the CNS space.

"It is Terran's goal to become an industry leader in neuropsychiatry by 
providing a suite of solutions for patients suffering from these diseases, 
which have not had many, if any, therapeutic options historically. With this 
acquisition from Concert, we get even closer to our goal," stated Dr. Sam 
Clark, Chief Executive Officer at Terran.  

These new chemical entities are covered by composition of matter patent 
applications. Financial terms of the deal were not disclosed.

About Terran Biosciences, Inc. 

Terran is a biotech platform company developing a portfolio of therapeutics and 
technologies for patients with neurological and psychiatric diseases. Backed by 
a number of life-science and tech investors, Terran has built a CNS-focused, 
tech-enabled drug development platform, and is rapidly advancing of number of 
late-stage assets, which include novel psychedelic-based therapeutics.

Terran Contact:

Investor Relations:
ir@terranbiosciences.com

Media:
info@terranbiosciences.com

Source: Terran Biosciences, Inc.